Nuvalent, Inc. (NUVL)
| Market Cap | 9.76B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -450.07M |
| Shares Out | 79.00M |
| EPS (ttm) | -6.05 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,989,426 |
| Open | 123.56 |
| Previous Close | 123.53 |
| Day's Range | 123.45 - 123.69 |
| 52-Week Range | 71.13 - 123.69 |
| Beta | 1.15 |
| Analysts | Hold |
| Price Target | 125.13 (+1.3%) |
| Earnings Date | Aug 6, 2026 |
About NUVL
Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are Zidesamtinib (NVL-520), a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the Phase 2 portion of... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 17 analysts, the average rating for NUVL stock is "Hold." The 12-month stock price target is $125.13, which is an increase of 1.30% from the latest price.
News
GSK announces commencement of tender offer to acquire Nuvalent
GSK (GSK) announced that Harmony Row Acquisition Co., a direct wholly-owned subsidiary of GlaxoSmithKline, which is an indirect wholly-owned subsidiary of GSK, has commenced a tender offer to purchase...
Nuvalent downgraded to Market Perform from Outperform at Bernstein
Bernstein downgraded Nuvalent (NUVL) to Market Perform from Outperform with a price target of $124, down from $172, after the company entered into an agreement to be acquired by GSK…
Nuvalent Transcript: AGM 2026
The meeting, held virtually, covered director elections, executive compensation, and auditor ratification. All proposals passed, with final results to be filed in Form 8-K. Forward-looking statements were made with reference to risk factors in SEC filings.
Biotech IPO window is opening but big pharma M&A still sets the pace, top bankers tell CNBC
Biotech investors are far more selective than they were during the pandemic-era boom, JPMorgan's top EMEA healthcare investment bankers told CNBC. Many biotech companies are now pursuing a dual-track...
Project Nashville: GSK boosts oncology rebuild with $11 billion Nuvalent deal
GSK's record $10.6 billion deal for U.S. company Nuvalent will accelerate the British drugmaker's rebuild of its cancer drug business as it seeks to fend off competition from bigger rivals AstraZenec...
Nuvalent downgraded to Neutral from Buy at Guggenheim
Guggenheim analyst Brad Canino downgraded Nuvalent (NUVL) to Neutral from Buy with a price target of $124, down from $151, citing the proposed acquisition by GSK for $124 per share…
Nuvalent downgraded to Neutral from Buy at UBS
UBS downgraded Nuvalent (NUVL) to Neutral from Buy with a price target of $124, down from $138, following GSK’s (GSK) all-cash acquisition deal for $10.6B or $124 per share. Published…
After shedding its cancer business just over a decade ago, GSK's new CEO is building back with a $10.6 billion deal
After shedding its oncology business just over a decade ago, GSK is building it back with a $10.6 billion deal.
Nuvalent downgraded to Hold from Buy at Truist
Truist downgraded Nuvalent (NUVL) to Hold from Buy with a price target of $124, down from $140, following GSK’s (GSK) all-cash acquisition deal for $10.6B or $124 per share. The…
Nuvalent downgraded to Hold from Buy at TD Cowen
TD Cowen analyst Marc Frahm downgraded Nuvalent (NUVL) to Hold from Buy with a $124 price target after GSK entered into an agreement to acquire the company for $124 per…
Nuvalent downgraded to Equal Weight from Overweight at Barclays
Barclays downgraded Nuvalent (NUVL) to Equal Weight from Overweight with a $124 price target after GSK entered into an agreement to acquire the company for $124 per share in cash…
Midday Fly By: OpenAI files for IPO, GSK to acquire Nuvalent
The major averages were broadly lower near noon despite oil prices pulling back, as yesterday’s surge in chip stocks failed to build on its momentum. The fresh pressure on companies…
Nuvalent downgraded to Hold from Buy at Canaccord
Canaccord analyst John Newman downgraded Nuvalent (NUVL) to Hold from Buy after GSK entered into an agreement to acquire the company for $124 per share in cash or $10.6B. Published…
Nuvalent downgraded to Neutral from Outperform at Baird
Baird downgraded Nuvalent (NUVL) to Neutral from Outperform with a price target of $122.85, down from $158, after GSK entered into an agreement to acquire the company for $124 per…
Nuvalent downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Anupam Rama downgraded Nuvalent (NUVL) to Neutral from Overweight with a price target of $124, down from $147, after GSK entered into an agreement to acquire the company…
Tuesday's Morning Movers: MU Rebounds, ON PT Increases & GSK Buys NUVL
Diane King Hall discusses this morning's top moving stocks by highlighting Micron (MU) as it rallies back after Friday's sell-off. She also touches on Wells Fargo raising its ON Semiconductor's (ON) p...
Nuvalent downgraded to Hold from Buy at Stifel
Stifel downgraded Nuvalent (NUVL) to Hold from Buy with a price target of $124, down from $135, after GSK (GSK) announced that it has entered into an agreement to acquire…
Nuvalent downgraded to Market Perform from Outperform at Raymond James
Raymond James downgraded Nuvalent (NUVL) to Market Perform from Outperform after this morning’s announcement of GSK’s (GSK) all-cash acquisition for $124 per share. The firm thinks GSK is paying “a…
Nuvalent downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright downgraded Nuvalent (NUVL) to Neutral from Buy with a price target of $124, down from $155, after GSK entered into an agreement to acquire Nuvalent for $124 per…
GSK's $10.6B Nuvalent takeover fails to impress investors as shares fall: here's why
GlaxoSmithKline is making its largest oncology acquisition in years with a $10.6 billion deal for US-based cancer drug developer Nuvalent, betting that a trio of promising lung cancer therapies can he...
Cancer-Drug Stock Jumps 39% on $10.6 Billion GSK Deal. Why It's a Surprise Move.
GSK is making a tender offer for Nuvalent at $124 a share in cash, a 40% premium to where the stock traded as of Monday's close.
London's FTSE 100 falls as GSK slides after Nuvalent deal
The UK's benchmark FTSE 100 index moved lower on Tuesday, pressured by losses in healthcare giant GSK after the company announced plans to acquire shares of US-based drug developer Nuvalent in a deal ...